View photo.Deutsche Bank on Thursday named its top Small-Cap Biotech picks for 2015. The top picks were selected because they were either a disruptive technology, a rare or orphan disease market, an unmet need market or a stock with a big-time catalyst.Here is what to watch for in Deutsche’s top picks.
PTC Therapeutics, Inc. (NASDAQ: PTCT
Deutsche highlighted PTC Therapeutics as its very top pick for 2015. PTC Therapeutics is expecting to release Phase 3 confirmatory trial data for Duchenne muscular dystrophy (DMD) in the second half of 2015.
Deutsche set a $75 price target.
Shares traded recently at $55.13, down 4.8 percent.
Related Link: The 5 Biggest Biotech Stocks
Alnylam Pharmaceuticals, Inc. (NASDAQ:
Alnylam is Deutsche’s favorite long-term pick. The company on Wednesday raised approximately $450 million through a public offering of about 4.7 million shares. Deutsche believes Anlylam’s pipeline has broad applicability.
Deutsche set a $155 price target.
Shares traded recently at $89.24, up 2.15 percent.
Achillion Pharmaceuticals, Inc. (NASDAQ:
Achillion is Deutsche’s most underappreciated stock in early 2015. Achillion is developing ACH-3422 (a nucleotide NS5B polymerase inhibitor) for HCV and Deutsche believes Phase 1 data released last year looked encouraging.
Achillion is expecting to release full data for ACH-3442 at a medical meeting in the first half of 2015.
Deutsche set a $25 price target.
Shares traded recently at $15.30, up 2.75 percent.
Genfit (EPA: GNFT)
Deutsche selected Genfit as its top pick in the first half of 2015. Genfit’s lead asset is GFT-505, which is being studied in treating NASH.
The company has an important binary Phase 2b data readout in March. Deutsche estimates a $30 billion peak global market potential for NASH and believe Genfit is a high-risk, high-reward stock in the sector.
Deutsche set a €110 price target.
Latest Ratings for PTCT
Bank of America
View More Analyst Ratings for PTCT
View the Latest Analyst Ratings
See more from Benzinga
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Investment & Company Information